These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 11129323)

  • 1. Behaviour of interleukin-2 serum levels in advanced non-small-cell lung cancer patients: relationship with response to therapy and survival.
    Orditura M; Romano C; De Vita F; Galizia G; Lieto E; Infusino S; De Cataldis G; Catalano G
    Cancer Immunol Immunother; 2000 Dec; 49(10):530-6. PubMed ID: 11129323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients.
    De Vita F; Orditura M; Galizia G; Romano C; Roscigno A; Lieto E; Catalano G
    Chest; 2000 Feb; 117(2):365-73. PubMed ID: 10669676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pretreatment Serum Albumin Level is an Independent Prognostic Factor in Patients with Stage IIIB Non-Small Cell Lung Cancer: A Study of the Turkish Descriptive Oncological Researches Group.
    Tanriverdi O; Avci N; Oktay E; Kalemci S; Pilanci KN; Cokmert S; Menekse S; Kocar M; Sen CA; Akman T; Ordu C; Goksel G; Meydan N; Barutca S
    Asian Pac J Cancer Prev; 2015; 16(14):5971-6. PubMed ID: 26320482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VEGF and TSP1 levels correlate with prognosis in advanced non-small cell lung cancer.
    Fleitas T; Martínez-Sales V; Vila V; Reganon E; Mesado D; Martín M; Gómez-Codina J; Montalar J; Reynés G
    Clin Transl Oncol; 2013 Nov; 15(11):897-902. PubMed ID: 23463593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy.
    Chang CH; Hsiao CF; Yeh YM; Chang GC; Tsai YH; Chen YM; Huang MS; Chen HL; Li YJ; Yang PC; Chen CJ; Hsiung CA; Su WC
    Int J Cancer; 2013 May; 132(9):1977-85. PubMed ID: 23034889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum levels of interleukin-6 as a prognostic factor in advanced non-small cell lung cancer.
    De Vita F; Orditura M; Auriemma A; Infusino S; Roscigno A; Catalano G
    Oncol Rep; 1998; 5(3):649-52. PubMed ID: 9538169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum chemokine network correlates with chemotherapy in non-small cell lung cancer.
    Yang D; Zhou J; Zeng T; Yang Z; Wang X; Hu J; Song Y; Chen L; Peer D; Wang X; Bai C
    Cancer Lett; 2015 Aug; 365(1):57-67. PubMed ID: 25976768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients.
    Correale P; Remondo C; Carbone SF; Ricci V; Migali C; Martellucci I; Licchetta A; Addeo R; Volterrani L; Gotti G; Rotundo MS; Tassone P; Sperlongano P; Abbruzzese A; Caraglia M; Tagliaferri P; Francini G
    Cancer Biol Ther; 2010 May; 9(9):685-93. PubMed ID: 20697196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival analysis in advanced non small cell lung cancer treated with platinum based chemotherapy in combination with paclitaxel, gemcitabine and etoposide.
    Natukula K; Jamil K; Pingali UR; Suresh Attili VS; Naidu Madireddy UR
    Asian Pac J Cancer Prev; 2013; 14(8):4661-6. PubMed ID: 24083721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the relationship between serum carcinoembryonic antigen level and treatment outcome in surgically resected clinical-stage I patients with non-small-cell lung cancer.
    Hotta K; Segawa Y; Takigawa N; Kishino D; Saeki H; Nakata M; Mandai K; Eguchi K
    Anticancer Res; 2000; 20(3B):2177-80. PubMed ID: 10928173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum levels of leptin and proinflammatory cytokines in advanced-stage non-small cell lung cancer.
    Tas F; Duranyildiz D; Argon A; Oğuz H; Camlica H; Yasasever V; Topuz E
    Med Oncol; 2005; 22(4):353-8. PubMed ID: 16260852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical significance of CXCL16 in the treatment of advanced non-small cell lung cancer.
    Shibata Y; Kobayashi N; Sato T; Nakashima K; Kaneko T
    Thorac Cancer; 2020 May; 11(5):1258-1264. PubMed ID: 32163231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 107 consecutive patients with limited- and extensive-stage non-small-cell lung cancer.
    Fetscher S; Brugger W; Engelhardt R; Kanz L; Hasse J; Frommhold H; Wenger M; Lange W; Mertelsmann R
    Ann Oncol; 1997 Jan; 8(1):57-64. PubMed ID: 9093708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuron-specific enolase (NSE) serum level in non small cell lung cancer--can it be an indicator of tumour chemosensitivity?
    Zych J; Sakowicz A; Radzikowska E; Załeska J; Rowińska-Zakrzewska E
    Rocz Akad Med Bialymst; 1997; 42 Suppl 1():173-8. PubMed ID: 9337535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitamin D receptor genetic variants are associated with chemotherapy response and prognosis in patients with advanced non-small-cell lung cancer.
    Xiong L; Cheng J; Gao J; Wang J; Liu X; Wang L
    Clin Lung Cancer; 2013 Jul; 14(4):433-9. PubMed ID: 23522953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line gemcitabine plus cisplatin in nonsmall cell lung cancer patients.
    Li Y; Wang LR; Chen J; Lou Y; Zhang GB
    Dis Markers; 2014; 2014():960458. PubMed ID: 24591771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cytostatic treatment of patients with advanced non-small cell lung cancer].
    Zych J; Radzikowska E; Załeska J; Obłakowski P; Słodkowska J; Rowińska-Zakrzewska E
    Pneumonol Alergol Pol; 1998; 66(1-2):73-8. PubMed ID: 9658884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The serum-based VeriStrat® test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients.
    Fidler MJ; Fhied CL; Roder J; Basu S; Sayidine S; Fughhi I; Pool M; Batus M; Bonomi P; Borgia JA
    BMC Cancer; 2018 Mar; 18(1):310. PubMed ID: 29558888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized control study of nedaplatin or cisplatin concomitant with other chemotherapy in the treatment of advanced non-small cell lung cancer.
    Li CH; Liu MY; Liu W; Li DD; Cai L
    Asian Pac J Cancer Prev; 2014; 15(2):731-6. PubMed ID: 24568487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between serum biomarkers CEA and LDH and response in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
    de Jong C; Deneer VHM; Kelder JC; Ruven H; Egberts TCG; Herder GJM
    Thorac Cancer; 2020 Jul; 11(7):1790-1800. PubMed ID: 32383328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.